Ultrasound Obstet Gynecol. 2014 Jan;43(1):25-33. doi: 10.1002/uog.12566.
To evaluate the efficacy and safety of monitoring controlled ovarian stimulation (COS) using ultrasonography.
We performed a search in April 2013 for randomized controlled trials (RCTs). Studies that compared different methods for monitoring COS, including ultrasound assessment of follicles (alone or combined with hormonal assessment), in at least one group were considered eligible.
The search retrieved 1515 records, six of which were eligible. Five studies were included that compared ultrasonography alone with ultrasonography and hormonal assessment (estradiol and/or progesterone) and one study compared 2D and 3D ultrasound monitoring. None of the included studies reported on live birth. Four of the five studies reported on clinical pregnancy (RR, 0.95; 95% CI, 0.78–1.16; n = 611); the confidence interval (CI) was somewhat wide, but allowed us to conclude that ultrasonography alone differs little from ultrasonography combined with hormonal assessment. Three studies reported on the number of oocytes retrieved (mean difference (MD), 0.8 oocytes; 95% CI, –0.4 to 2.0; n = 474); the CI was somewhat wide and did not permit us to conclude whether ultrasonography alone is better than or similar to ultrasonography and hormonal assessment for this outcome. All five studies reported on ovarian hyperstimulation syndrome (OR, 1.02; 95% CI, 0.47–2.25; n = 725) and only one study reported on miscarriage (RR, 0.37; 95% CI, 0.07–1.79; n = 45); for these two outcomes, the CI was very wide and did not permit us to conclude whether ultrasonography alone is better, similar or less effective than ultrasonography combined with hormonal assessment. For the study comparing 2D and 3D ultrasound, the reported outcomes were clinical pregnancy (RR, 1.00; 95% CI, 0.58–1.73, n = 72) and the number of oocytes retrieved (MD, –0.4 oocytes; 95% CI, –3.6 to 2.9; n = 72); for both, the CI was very wide and did not permit us to conclude whether use of 3D ultrasound is better, similar or less effective than use of 2D ultrasound.
Current evidence suggests that monitoring COS only with ultrasonography is unlikely to substantially alter the chances of achieving a clinical pregnancy and the number of oocytes retrieved is similar to that when monitoring with ultrasonography and hormonal assessment. For the other outcomes and comparisons, the available data are inconclusive. We believe that more studies evaluating the optimal procedure for monitoring COS are needed.
评估超声监测控制性卵巢刺激(COS)的疗效和安全性。
我们于 2013 年 4 月进行了一次检索,纳入了比较不同 COS 监测方法的随机对照试验(RCT),这些方法包括卵泡的超声评估(单独或联合激素评估)。
检索到 1515 条记录,其中 6 条符合纳入标准。纳入的 6 项研究中,有 5 项比较了超声单独与超声联合激素评估(雌二醇和/或孕酮)的效果,1 项研究比较了 2D 与 3D 超声监测。纳入的研究均未报告活产。5 项研究中的 4 项报告了临床妊娠(RR,0.95;95%CI,0.78-1.16;n=611);置信区间(CI)较宽,但我们可以得出结论,超声单独与超声联合激素评估的效果差异不大。3 项研究报告了获卵数(均数差值(MD),0.8 个;95%CI,-0.4 至 2.0;n=474);CI 较宽,不能得出超声单独是否优于或等同于超声联合激素评估的结论。5 项研究均报告了卵巢过度刺激综合征(OR,1.02;95%CI,0.47-2.25;n=725),仅有 1 项研究报告了流产(RR,0.37;95%CI,0.07-1.79;n=45);这两个结局的 CI 很宽,不能得出超声单独是否优于或等同于超声联合激素评估的结论。比较 2D 与 3D 超声的研究报告了临床妊娠(RR,1.00;95%CI,0.58-1.73,n=72)和获卵数(MD,-0.4 个;95%CI,-3.6 至 2.9;n=72);这两个结局的 CI 均很宽,不能得出 3D 超声是否优于或等同于 2D 超声的结论。
现有证据表明,仅用超声监测 COS 不太可能显著改变临床妊娠的机会,获卵数与超声联合激素评估相似。对于其他结局和比较,现有数据尚无定论。我们认为,需要更多评估 COS 监测最佳方法的研究。